Inhaled nitric oxide combined with prostacyclin and adrenomedullin in acute respiratory failure with pulmonary hypertension in piglets

Pediatric Pulmonology

Volumn 42, Issue 11, 2007, Pages 1048-1056

  Dani, Carlo ^a   Pavoni, Vittorio ^a   Corsini, Iuri ^a   Longini, Mariangela ^b   Gori, Gabriele ^a   Giannesello, Lara ^a   Perna, Avio ^a   Gritti, Gaetano ^a   Paternostro, Ferdinando ^c   Forestieri, Annalisa ^c   Buonocore, Giuseppe ^b   Rubaltelli, Firmino F ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adrenomedullin; Nitric oxide; Oxidative stress; Prostacyclin; Pulmonary hypertension; Surfactant

Indexed keywords

ADRENOMEDULLIN; LUNG SURFACTANT; NITRIC OXIDE; PROSTACYCLIN;

ACUTE RESPIRATORY FAILURE; AEROSOL; AIRWAY RESISTANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHUS; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL MODEL; FEMALE; HEMODYNAMIC MONITORING; LUNG ARTERY PRESSURE; LUNG ASPIRATION; LUNG COMPLIANCE; LUNG MECHANICS; MALE; NONHUMAN; OXIDATIVE STRESS; OXYGENATION; PATIENT COMPLIANCE; PIGLET; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZATION; TIDAL VOLUME;

ADMINISTRATION, INHALATION; ADRENOMEDULLIN; ANIMALS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HYPERTENSION, PULMONARY; MALE; NITRIC OXIDE; PULMONARY ARTERY; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY FUNCTION TESTS; SUS SCROFA; VASODILATOR AGENTS;

EID: 36248998276     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20695     Document Type: Article

References (46)

1. Lorch SA, Cnaan A, Barnhart K. Cost-effectiveness of inhaled nitric oxide for the management of persistent pulmonary hypertension of the newborn. Pediatrics 2004;114:417-426.
2. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2001;4: CD000399.
3. Clark RH, Kueser TJ, Walker MW, Southgate WM, Huckaby JL, Perez JA, Roy BJ, Keszler M, Kinsella JP. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med 2000;342:469-474.
4. The Neonatal Inhaled Nitric Oxide Study Group. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. N Engl J Med 1997;336:597-604.
5. Mikhail G, Gibbs J, Richardson M, Wright G, Khaghani A, Banner N, Yacoub M. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997;18:1499-1504.
6. Zobel G, Dacar D, Rodl S, Friehs I. Inhaled nitric oxide versus inhaled prostacyclin and intravenous versus inhaled prostacyclin in acute respiratory failure with pulmonary hypertension in piglets. Pediatr Res 1995;38:198-204.
7. Hill L, Pearl R. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol 1999;86:1160-1164.
8. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr 2002; 141:830-832.
9. Kapas S, Catt KJ, Clark AJ. Cloning and expression of cDNA encoding a rat adrenomedullin receptor. J Biol Chem 1995;270: 25344-25347.
10. Owji AA, Smith DM, Coppock HA, Morgan DG, Bhogal R, Ghatei MA, Bloom SR. An abundant and specific binding site for the novel vasodilator adrenomedullin in the rat. Endocrinology 1995;136:2127-2134.
11. Kandier MA, Von Der Hardt K, Mahfoud S, Chada M, Schoof E, Papadopoulos T, Rascher W, Dotsch J. Pilot intervention: Aerosolized adrenomedullin reduces pulmonary hypertension. J Pharmacol Exp Ther 2003;306:1021-1026.
12. Ishizaka Y, Ishizaka Y, Tanaka M, Kitamura K, Kangawa K, Minamino N, Matsuo H, Eto T. Adrenomedullin stimulates cyclic AMP formation in rat vascular smooth muscle cells. Biochem Biophys Res Commun 1994;200:642-646.
13. Magnusson A, Halldorsson H, Thorgeirsson G, Kjeld M. Endothelin secretion is regulated by cyclic AMP and phosphatase 2A in endothelial cells. J Cell Physiol 1994;161:429-434.
14. Weinberger B, Fakhrzadeh L, Heck DE, Laskin JD, Gardner CR, Laskin DL. Inhaled nitric oxide primes lung macrophages to produce reactive oxygen and nitrogen intermediates. Am J Respir Crit Care Med 1998;158:931-938.
15. Broccard AF, Feihl F, Vannay C, Marken M, Hotchkiss J, Schaller MD. Effects of L-NAME and inhaled nitric oxide on ventilator-induced lung injury in isolated, perfused rabbit lungs. Crit Care Med 2004;32:1872-1878.
16. Hallman M, Bry K, Turbow R, Waffarn F, Lappalainen U. Pulmonary toxicity associated with nitric oxide in term infants with severe respiratory failure. J Pediatr 1998;132:827-829.
17. Van Meurs KP, Cohen TL, Yang G, Somaschini M, Kuruma P, Dennery PA. Inhaled NO and markers of oxidant injury in infants with respiratory failure. J Perinatol 2005;25:463-469.
18. Storme L, Zerimech F, Riou Y, Martin-Ponthieu A, Devisme L, Slomianny C, Klosowski S, Dewailly E, Cneude F, Zandecki M, Dupuis B, Lequien P. Inhaled nitric oxide neither alters oxidative stress parameters nor induces lung inflammation n in premature lambs with moderate hyaline membrane disease. Biol Neonate 1998;73:172-181.
19. Turanlahti M, Pesonen E, Lassus P, Andersson S. Nitric oxide and hyperoxia in oxidative lung injury. Acta Paediatr 2000;89:966-970.
20. Hamon I, Fresson J, Nicolas MB, Buchweiller MC, Franck P, Hascoet JM. Early inhaled nitric oxide improves oxidative balance in very preterm infants. Pediatr Res 2005;57:637-643.
21. Crow JP, Beckman JS. The role of peroxynitrite in nitric oxide-mediated toxicity. Curr Top Microbiol Immunol 1995;196:57-73.
22. Haddad IY, Ischiropoulos H, Holm BA, Beckman JS, Baker JR, Matalon S. Mechanisms of peroxynitrite-induced injury to pulmonary surfactants. Am J Physiol 1993; L555-L564.
23. Ballard PL, Gonzales LW, Godinez RI, Godinez MH, Savani RC, McCurnin DC, Gibson LL, Yoder BA, Kerecman JD, Grubb PH, Shaul PW. Surfactant composition and function in a primate model of infant chronic lung disease: Effects of inhaled nitric oxide. Pediatr Res 2006;59:157-162.
24. Di Renzo M, Pieragalli D, Meini S, De Franco V, Pompella G, Auteri A, Pasqui AL. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6. Prostaglandins Leukot Essent Fatty Acids 2005;73:405-410.
25. Shinmura K, Tamaki K, Sato T, Ishida H, Bolli R. Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor. Am J Physiol Heart Circ Physiol 2005;288:H2093-H2101.
26. Cui X, Wu R, Zhou M, Dong W, Ulloa L, Yang H, Wang H, Tracey KJ, Simms HH, Wang P. Adrenomedullin and its binding protein attenuate the proinflammatory response after hemorrhage. Crit Care Med 2005;33:391-398.
27. Wong LY, Cheung BM, Li YY, Tang F. Adrenomedullin is both proinflammatory and antiinflammatory: Its effects on gene expression and secretion of cytokines and macrophage migration inhibitory factor in NR8383 macrophage cell line. Endocrinology 2005;146:1321-1327.
28. Yoshimoto T, Gochou N, Fukai N, Sugiyama T, Shichiri M, Hirata Y. Adrenomedullin inhibits angiotensin II-induced oxidative stress and gene expression in rat endothelial cells. Hypertens Res 2005;28:165-172.
29. Lachman B, Robertson B, Vogel J. In vivo lung lavage as an experimental model of the respiratory distress syndrome. Acta Anesthesiol Scand 1980;24:231-236.
30. Buonocore G, Perrone S, Longini M, Terzuoli L, Bracci R. Total hydroperoxide and advanced oxidation protein products in preterm hypoxic babies. Pediatr Res 2000;47:221-224.
31. Witko-Sarsat V, Freidlander M, Capeillere-Blandin C, Nguyen-Khoa T, Thu Nguyen A, Zingraff J, Jungers P, Descamps-Latsca B. Advanced oxidation protein product as a novel marker of oxidative stress in uremia. Kidney Int 1996;49:1304-1313.
32. Kime R, Gibson A, Yong W, Hider R, Powers H. Chromatographic method for the determination of non-transferrin-bound iron suitable for use on the plasma and bronchoalveolar lavage fluid of preterm babies. Clin Sci 1996;91:633-638.
33. Lema G, Dryja D, Vargas I, Enhorning G. Pseudomonas aeruginosa from patients with cystic fibrosis affects function of pulmonary surfactant. Pediatr Res 2000;47:121-126.
34. Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989;65:1-21.
35. Kadowitz PJ, Chapnick BM, Feigen LP, Hyman AL, Nelson PK, Spannhake EW. Pulmonary and systemic vasodilator effects of the newly discovered prostaglandin, P GI2. J Appl Physiol 1978; 45:408-413.
36. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: A randomised trial in infants after cardiac surgery. Intensive Care Med 2003;29:1996-2003.
37. Parker TA, Ivy DD, Kinsella JP, Torielli F, Ruyle SZ, Thilo EH, Abman SH. Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia. Am J Respir Crit Care Med 1997;155:743-746.
38. Zayek M, Cleveland D, Morin FC, III. Treatment of persistent pulmonary hypertension in the newborn lamb by inhaled nitric oxide. J Pediatr 1993;122:743-750.
39. Dupuy PM, Shore SA, Drazen JM, Frostell C, Hill WA, Zapol WM. Bronchodilator action of inhaled nitric oxide in guinea pigs. J Clin Invest 1992;90:421-428.
40. Potter CF, Dreshaj IA, Haxhiu MA, Stork EK, Chatburn RL, Martin RJ. Effect of exogenous and endogenous nitric oxide on the airway and tissue components of lung resistance in the newborn piglet. Pediatr Res 1997;41:886-891.
41. Athavale K, Claure N, D'Ugard C, Everett R, Swaminathan S, Bancalari E. Acute effects of inhaled nitric oxide on pulmonary and cardiac function in preterm infants with evolving bronchopulmonary dysplasia. J Perinatal 2004;24:769-774.
42. McCurnin DC, Pierce RA, Chang LY, Gibson LL, Osborne-Lawrence S, Yoder BA, Kerecman JD, Albertine KH, Winter VT, Coalson JJ, Crapo JD, Grubb PH, Shaul PW. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol 2005;288:L450-L459.
43. Ragaller M, Bleyl J, Tscho U, Winkler T, Regner M, Rasche S, Koch T, Albrecht M. Effects of inhalation of perfluorocarbon aerosol on oxygenation and pulmonary function compared to PGI2 inhalation in a sheep model of oleic acid-induced lung injury. Intensive Care Med 2001;27:889-897.
44. Kanazawa H, Kurihara N, Hirata K, Kudoh S, Kawaguchi T, Takeda T., Adrenomedullin, a newly discovered hypotensive peptide, is a potent bronchodilator. Biochem Biophys Res Commun 1994;205:251-254.
45. Ohbayashi H, Suito H, Yoshida N, Ilto Y, Kume H, Yamaki K. Adrenomedullin inhibits ovalbumin-induced bronchoconstriction and airway microvascular leakage in guinea-pigs. Eur Respir J 1999;14:1076-1081.
46. Weinberger B, Laskin DL, Heck DE, Laskin JD. The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:5-16.